Nucana (NCNA) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
NuCana’s recent Phase 1b/2 study results reveal promising efficacy of its new drug NUC-3373 in combination with pembrolizumab and docetaxel for patients with advanced solid tumors and lung cancer, respectively. Notably, patients who had exhausted other treatments demonstrated significant tumor reduction and prolonged progression-free survival. These developments could position NUC-3373 as a valuable option for hard-to-treat cancer cases, potentially impacting NuCana’s market performance.
For further insights into NCNA stock, check out TipRanks’ Stock Analysis page.